Heat Biologics, Inc.
(NASDAQ : HTBX)

( )
HTBX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.88%93.921.3%$988.55m
BIIBBiogen Inc.
2.45%229.891.3%$619.18m
AMGNAmgen Inc.
1.22%180.481.3%$474.61m
GILDGilead Sciences, Inc.
2.13%64.140.9%$448.87m
ILMNIllumina, Inc.
1.49%319.203.5%$295.43m
REGNRegeneron Pharmaceuticals, Inc.
2.80%349.992.6%$291.08m
VRTXVertex Pharmaceuticals Incorporated
1.18%174.611.9%$236.35m
ALXNAlexion Pharmaceuticals, Inc.
4.30%135.682.0%$176.60m
EXASExact Sciences Corporation
0.27%95.3925.3%$169.11m
AAgilent Technologies, Inc.
1.23%76.721.6%$147.38m
SRPTSarepta Therapeutics, Inc.
1.74%120.2214.7%$129.47m
ONCESpark Therapeutics, Inc.
0.64%111.3811.2%$116.56m
INCYIncyte Corporation
0.57%73.942.5%$97.68m
IONSIonis Pharmaceuticals, Inc.
0.72%73.868.3%$96.82m
BMRNBioMarin Pharmaceutical Inc.
-0.21%85.314.3%$92.88m

Company Profile

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Durham, NC.